Testing JCXH-213 for B-cell lymphoma that returned or didn't respond
Part of Cancer clinical trials.
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell non-Hodgkin lymphoma (like diffuse large B-cell lymphoma or follicular lymphoma) that came back or didn't respond to treatment
- Your lymphoma cells have a protein called CD19
- You are well enough to be up and about at least half the day (ECOG score 0 or 1)
- You have at least one tumor that can be measured on scans (like a lymph node bigger than 1.5 cm)
- Your lymphoma has not spread to your brain or spinal cord
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy called JWCAR239 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. It aims to see if this personalized immune cell treatment can help shrink tumors and control the disease.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Hear when a new B-Cell Non-Hodgkin Lymphoma-Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.